If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Anxiety disorders === Escitalopram appears to be effective in treating generalized anxiety disorder, with relapse on escitalopram at 20% rather than placebo at 50%, which translates to a number needed to treat of 3.33. Escitalopram appears effective in treating social anxiety disorder as well.
Vacuum microwave drying is used for the US Army's experimental Close Combat Assault Ration. Freeze drying or lyophilization is a drying method where the solvent is frozen prior to drying and is then sublimed, i.e., passed to the gas phase directly from the solid phase, below the melting point of the solvent. It is increasingly applied to dry foods, beyond its already classical pharmaceutical or medical applications. It keeps biological properties of proteins, and retains vitamins and bioactive compounds. Pressure can be reduced by a high vacuum pump (though freeze drying at atmospheric pressure is possible in dry air). If using a vacuum pump, the vapor produced by sublimation is removed from the system by converting it into ice in a condenser, operating at very low temperatures, outside the freeze drying chamber. Supercritical drying (superheated steam drying) involves steam drying of products containing water. This process is feasible because water in the product is boiled off, and joined with the drying medium, increasing its flow. It is usually employed in closed circuit and allows a proportion of latent heat to be recovered by recompression, a feature which is not possible with conventional air drying, for instance. The process has potential for use in foods if carried out at reduced pressure, to lower the boiling point. Natural air drying takes place when materials are dried with unheated forced air, taking advantage of its natural drying potential.
"If the prepotency of Peru, if its population and resources were worth, as Santa Cruz has claimed, to justify its policy, the government in charge of Foreign Relations of the Argentine Confederation would seize them to justify the war against the Peruvian Confederation. -Bolivian (...) if there was no balance between Peru and Bolivia, will it exist between the United States and the Argentine Confederation? (...) that fusion under the aegis of a conqueror is dangerous and the propensity of Peru to aggrandize it does not promise Bolivia neither security nor rest."
== Other uses == lh (digraph), in many languages Bristol LH, a type of British bus manufactured between 1967 and 1982 Chrysler LH platform, a type of Chrysler car made from 1993 through 2004 Late Helladic, a period in the history of ancient Greece, during the Bronze Age Leasehold, or tenure, in property law Left-handed, or left hand Letterhead, a heading at the top of a sheet of letter paper Lewis Hamilton (born 1985), British racing driver
==== Binding of fluoxetine to LeuT protein ==== Both enantiomers of fluoxetine show a similar affinity for SERT. However, NE:5HT selective ratio gives the impression that the (S)-enantiomer is 100 times more selective for SERT inhibition than the (R)-enantiomer. The (R)-(+)-stereoisomer is almost 8 times more potent an inhibitor of SERT together with a longer duration of action than the (S)-(−)-isomer. (S)-(−)-norfluoxetine metabolite is seven times more potent an inhibitor on 5-HT transporter then (R)-(+)-metabolite, with selectivity ratio almost equivalent to that of (S)-fluoxetine. Both enantiomers of fluoxetine bind to the extracellular vestibule on the LeuT protein is such a way that the three fluorine atoms of the methylphenoxy ring bind into the HBP that is formed by Leu25, Gly26, Leu29, Arg30 and Tyr108. The halogens additionally make Van der Waals interaction with Leu29 and Tyr108, where the (S)-enantiomer additionally binds to Phe253 and makes Van der Waals contact with it among with previously mentioned amino acids. Because of the (S)-enantiomers opposite chirality to the (R)-enantiomer the rest of the molecule is reversed in the HBP, where the amine tail points towards the extracellular space and interacts with the N-terminal of Leu400, Asp401 and Ala319 (amino acids which are a part of the TM10). In this LeuT bound form the complex is rather rigid.
Sources: en.wikipedia.org
=== Legal status === Eptinezumab was approved for medical use in the United States in February 2020. In November 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization for the medicinal product Vyepti, intended for the prophylaxis of migraine. The applicant for this medicinal product is H. Lundbeck A/S. Eptinezumab was approved for medical use in the European Union in January 2022.
== Signs and symptoms == Signs and symptoms of TIA are widely variable and can mimic other neurologic conditions, making the clinical context and physical exam crucial in ruling in or out the diagnosis. The most common presenting symptoms of TIA are focal neurologic deficits, which can include, but are not limited to:
== Contamination incidents == The company has been involved in several controversial incidents of proven and alleged corporate crimes, including exposing workers and residents of an entire town to asbestos contamination in Libby and Troy, Montana, water contamination (the basis of the book and film A Civil Action) in Woburn, Massachusetts, and an Acton, Massachusetts, Superfund site.
== Notable people with sleep apnea == Joe Biden – Former President of the United States, who uses a CPAP machine to manage a history of obstructive sleep apnea dating back to 2008. Jack Black – American actor and musician, who publicly discussed navigating his diagnosis and his reliance on a CPAP machine. Brett Favre – Hall of Fame NFL quarterback, who noted that his diagnosis of obstructive sleep apnea and subsequent daytime fatigue contributed to his decision to retire from professional football. Carrie Fisher – American actress and author, whose official coroner's report cited sleep apnea as a primary contributing factor in her 2016 death. Shaquille O'Neal – Hall of Fame NBA basketball player, who partnered with Harvard Medical School to produce public health materials after being diagnosed with severe obstructive sleep apnea. Amy Poehler – Emmy-winning actress and writer, who openly detailed her severe, exhausting experiences with the sleep condition in her autobiography. Tyler Reddick – American racing driver, who partnered with a CPAP company after being diagnosed with OSA. Reggie White – NFL defensive lineman, whose death at age 43 from cardiac arrhythmia was heavily attributed to complications from untreated sleep apnea, prompting his widow to found a national sleep education foundation that also provides affordable CPAP equipment to those who might otherwise be unable to pay for it.
The key intermediate step of these cyclometalation reactions involves the metal-mediated cleavage of the C–H bond and simultaneous formation of the metal–C bond of the substrate. Upon addition of substrate, the N-acyl motif acts as an internal proton acceptor in the concerted metal-deprotonation (CMD) of the transition state for this inner-sphere process. According to this model, the rate and selectivity of the C–H functionalization are impacted by the basicity of the MPAA ligand. The resulting experimental data of steric and electronic alteration of the MPAA ligands align with this model. In 2023, the first experimental observations to support the proposed mechanism were reported, which were previously unattainable due to the lack of well-defined isolated palladium-MPAA complexes.
Sources: en.wikipedia.org
Molecular analysis of CPOX is the best way to identify these patients, as they will not express a biochemical phenotype on laboratory testing unless they are symptomatic. Identification of asymptomatic patients allows them to adjust their lifestyle to avoid common triggering factors.
guanine-cytosine content Also abbreviated GC-content. The proportion of nitrogenous bases in a nucleic acid that are either guanine (G) or cytosine (C), typically expressed as a percentage. DNA and RNA molecules with higher GC-content are generally more thermostable than those with lower GC-content due to molecular interactions that occur during base stacking.
== Diplomatic maneuvers (1971–1972) == In late 1970, Nixon and Kissinger became concerned that the North Vietnamese would launch a major offensive in 1972 to coincide with presidential election, making it imperative to cut the Ho Chi Minh Trail in 1971 to prevent the Communists from building up their forces. As the Cooper–Church Amendment had forbidden U.S. troops from fighting in Laos, the plans that were conceived called for South Vietnamese troops with American air support to invade Laos to sever the Ho Chi Minh Trail in an operation code-named Lam Son 719. Kissinger wrote about Lam Son: "The operation, conceived in doubt and assailed by skepticism, proceeded in confusion". In the first major test of Vietnamization, the ARVN failed miserably. The ARVN invaded Laos on 8 February 1971 and were stopped decisively by the North Vietnamese. The majority of the ARVN officers were men who began their careers fighting for the French and retained the mentalité de colonisé, automatically deferring to any white man present be he French or American. Without the American advisers to tell them what to do, the ARVN officers tended to freeze up with fear and paralysis as had happened during Lam Son 719. By contrast, the officers of the PAVN had begun their careers fighting against the French, and were accustomed to think for themselves, which gave them the edge over the ARVN. Additionally, the U.S. Army had estimated that cutting the Ho Chi Minh Trail in Laos would require 4 U.S.
Transcutaneous oxygen measurement (TCOM or TcPO2) is a non-invasive method of measuring the oxygen level of the tissue below the skin. Since oxygen is carried by the blood, TCOM can be used as an indirect measure of blood flow to the tissue. Since blood flow is important for wound healing, TCOM is often used to gauge the ability of tissue to effectively heal. To perform the test, one set of electrodes are placed on viable tissue (e.g. the chest) as a control and a second set is placed around the tissue in question (e.g. legs or feet). The electrodes may mildly heat the skin to increase blood flow into the area. Oxygen may also be given to the patient to see if that increases oxygen levels in the tissue. The test takes about 45 minutes. Results are reported either as the absolute values of the tissue in question (in mmHg) or as a ratio of the tissue in question to the control tissue. The normal oxygen tension in the foot is approximately 60 mmHg, and the normal chest/foot ratio is approximately 0.9. Many factors can limit the accuracy of the test including edema, temperature, inflammation, medications, and stress. In addition for the measurement to be normal, all parts of the oxygenation pathway must be functioning: the lungs must be able to oxygenate the blood, the heart must be able to pump the blood, and a patent artery must be able to carry blood to the skin. Without comorbidities, wounds are thought to be able to heal if the oxygen tension is greater than 40 mmHg. In the presence of comorbidities, such as diabetes or edema, a higher value is likely needed.
The B1 receptor (also called bradykinin receptor B1) is expressed only as a result of tissue injury, and is presumed to play a role in chronic pain. This receptor has been also described to play a role in inflammation. It was shown that the kinin B1 receptor recruits neutrophils via the chemokine CXCL5 production. Moreover, endothelial cells have been described as a potential source for this B1 receptor-CXCL5 pathway. The B2 receptor is constitutively expressed and participates in bradykinin's vasodilatory role. The kinin B1 and B2 receptors belong to G protein coupled receptor (GPCR) family.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.